SCHEMBL30478271

SCHEMBL30478271

Cc1nc(Cl)cc(Cl)c1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GPR119 Q8TDV5 2/20 0.44
HDAC4 P56524 1/20 0.41
STS P08842 1/20 0.40
PARP1 P09874 1/20 0.40
DPP4 P27487 1/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP3A5 P20815 1/20 0.40
CCNK O75909 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCND3 P30281 1/20 0.40
CDK9 P50750 1/20 0.40
CDK6 Q00534 1/20 0.40
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25738732 1.00 POLB (0.49) POLBMEN1KMT2AGPR119HDAC4
SCHEMBL30496260 0.85 GPR119 (0.51) POLBMEN1KMT2AGPR119PARP1
SCHEMBL25283318 0.85 GPR119 (0.51) POLBMEN1KMT2AGPR119PARP1
SCHEMBL25295073 0.81 SPR (0.40) POLBMEN1KMT2ALMNATP53
SCHEMBL25237261 0.81 POLB (0.47) POLBMEN1KMT2AGPR119HDAC4
SCHEMBL30496267 0.81 POLB (0.47) POLBMEN1KMT2AGPR119HDAC4
SCHEMBL10248751 0.77 MEN1 (0.54) POLBMEN1KMT2AGPR119HDAC4
SCHEMBL25289195 0.77 CNR1 (0.39) KMT2AMAPTLMNA
SCHEMBL30496268 0.77 CNR1 (0.39) KMT2AMAPTLMNA
SCHEMBL19968008 0.76 MEN1 (0.59) POLBMEN1KMT2AGPR119HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 US disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 EP disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
WO-2023119233-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 POLB 2336/4885MEN1 2177/4885KMT2A 884/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 POLB 2336/4885MEN1 2177/4885KMT2A 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.